Welcome to our dedicated page for Marpai SEC filings (Ticker: MRAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Marpai, Inc. (MRAI) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Marpai’s filings describe its business as a technology platform company operating subsidiaries that provide Third-Party Administration (TPA), Pharmacy Benefit Management (PBM) and value-oriented health plan services to employers that directly pay for employee health benefits. Its Class A common stock is listed on the OTCQX Market under the symbol MRAI.
Through periodic and current reports, Marpai presents financial statements, details of its operating performance and information about its capital structure. For example, Form 8-K filings included in this record describe private placements of Class A common stock and warrants under Securities Purchase Agreements, with proceeds intended for working capital and general corporate purposes. Other 8-K filings reference amendments to the company’s certificate of incorporation, such as the authorization of blank-check preferred stock, and the release of selected financial information for specific reporting periods.
Annual proxy materials, such as the definitive proxy statement (DEF 14A), outline governance matters, including the election of directors, ratification of the independent registered public accounting firm and proposals to amend the certificate of incorporation. These documents also confirm key facts such as Marpai’s Delaware incorporation, its Tampa, Florida office location and the voting rights associated with its Class A common stock.
On this page, users can review Marpai’s Forms 10-K and 10-Q (when available), current reports on Form 8-K, proxy statements and other filings. Stock Titan’s tools can surface summaries and key points from longer documents, helping readers understand topics such as equity issuances, changes to the capital structure, governance proposals and how Marpai presents its TPA and PBM operations in official filings.
Marpai, Inc. (MRAI) director Robert Pons reported equity awards on a Form 4. On 10/20/2025, he acquired an aggregate 225,000 Class A common shares via RSUs at $0: 50,000 RSUs deemed fully vested on issuance; 75,000 RSUs vesting over nine months (25,000 at each three‑month interval); and 100,000 RSUs with 50,000 vested on issuance and 50,000 vesting upon the Company’s uplisting to Nasdaq.
Following these transactions, beneficial ownership was 309,200 shares as of 10/20/2025. These entries reflect stock-based compensation mechanics and vesting conditions rather than open-market purchases.
Marpai, Inc. (MRAI) reported an insider equity award. A director acquired 75,000 shares of Class A common stock on 10/20/2025 at a reported price of $0, reflecting settlement of restricted stock units.
Following this transaction, the reporting person beneficially owns 142,500 shares, held directly. The filing adds that the RSUs were deemed fully vested on the issuance date, indicating immediate vesting and delivery of shares.
Marpai, Inc. (MRAI): Schedule 13D/A Amendment No. 11 updates the ownership of Damien Lamendola and affiliated entities. Lamendola reports beneficial ownership of 7,501,528 shares, representing 40.51% of Marpai’s Class A common stock.
The filing attributes holdings to (i) 400,000 shares held directly by Lamendola, (ii) 6,109,893 shares held by HillCour Investment Fund, LLC, (iii) 931,674 shares held by WellEnterprises USA, LLC, and (iv) options for 62,500 shares at a $4.44 exercise price, of which 59,961 are vested. HillCour Investment Fund, LLC and WellEnterprises USA, LLC each report 7,041,567 shares beneficially owned (collective 38.03%).
The amendment notes share purchases in 2025: 86,805 (July 17), 371,470 (July 29), 896,903 (Sept 10), and 147,058 (Sept 30) pursuant to securities purchase agreements. Shares outstanding were 18,515,572 as of October 22, 2025.
Marpai, Inc. filed an amended Schedule 13G reporting that investment adviser Christopher M. Plahm has beneficial ownership of 572,359 shares of common stock, representing 3.10% of the class as of December 31, 2024. The filing shows shared voting power over these shares and no sole voting or dispositive power.
Holdings are attributed to advisory clients including Tall Pines Capital, LLC with 545,759 shares (2.96%) and Stonebridge Wealth Management, LLC with 26,600 shares (0.14%). The certification states the securities were not acquired to change or influence control.
Marpai, Inc. amended its charter to authorize 2,000,000 shares of blank-check preferred stock. This gives the board the ability to create one or more series of preferred shares with voting powers, preferences, and other rights set solely by the board.
The board approved the amendment on June 24, 2025; a majority of stockholders approved it at the annual meeting on August 27, 2025; and the amendment was filed in Delaware on October 17, 2025.
Marpai, Inc. (MRAI) — insider share sales reported. A reporting person filed a Form 4 showing open‑market sales of Common Shares on multiple dates: 10,000 shares at $1.43 on 08/13/2025; 20,000 at $1.40 on 08/15/2025; 20,000 at $1.40 on 08/18/2025; 20,000 at $1.40 on 08/19/2025; 10,000 at $1.42 on 08/20/2025; and 14,000 at $1.63 on 10/06/2025. Following the reported transactions, the filing lists 1,770,707 shares beneficially owned. The reporting person is indicated as a Director. Footnotes state the shares are held by IFCM MicroCap Fund LP, with Intelligent Fanatics Capital Management LLC as general partner; Mr. Cassel may be deemed a beneficial owner through shared voting and investment power and disclaims beneficial ownership except to the extent of his interests.
Marpai, Inc. (MRAI) filed an Form 8-K reporting a material event that attaches a Form of Securities Purchase Agreement as Exhibit 10.1 and an inline XBRL cover page file as Exhibit 104. The filing lists corporate communications categories related to securities and solicitation rules and identifies the security as Class A Common Stock traded on OTCQX. The form is signed by Damien Lamendola, Chief Executive Officer, with a signature date of October 6, 2025. The filing text supplied here does not include the agreement terms, financing amounts, counterparties, or other transaction economics, so material financial details are not available in this excerpt.
Marpai, Inc. (MRAI) director and CEO Damien Lamendola reported transactions dated 09/30/2025. He acquired 147,058 shares of Class A common stock at $1.36 per share and disposed of 800,000 shares on the same date. After these reported transactions, his beneficial ownership is stated as 6,419,893 shares, held indirectly through entities he controls as described in the footnotes. The filing shows two indirect holdings: shares held by HillCour Investment Fund, LLC (managed by Mr. Lamendola) and shares held by WellEnterprises USA, LLC, which is controlled through HillCour affiliates. The form is signed by Mr. Lamendola.
Marpai, Inc. director, Chief Executive Officer, and over-10% holder Damien Lamendola reported an indirect open‑market purchase of 896,903 shares of Class A common stock at an average price of $1.0592 per share. The shares are held by entities including HillCour Investment Fund, LLC and WellEnterprises USA, LLC, over which he holds voting and dispositive power. Following these transactions, his reported holdings include 6,272,835 indirect shares, 800,000 direct shares, and an additional 931,674 indirect shares of Class A common stock.
Marpai, Inc. (MRAI) director Shiv Sagiv amended a Form 4 to correct reported beneficial ownership after the vesting of restricted stock units (RSUs). The amendment shows 75,000 Class A common shares were acquired on 08/19/2025 through RSU vesting at no cash price, and the Reporting Person now beneficially owns 147,000 shares. The filing states the RSUs vested in three equal tranches of 25,000 shares at three, six and nine months after the grant date, and the amendment corrects an earlier filing that misstated the post-transaction ownership total.